Thursday, February 13, 2014 1:27:37 AM
From Oct 2013 ::: The innovation award we won from OTC Bulletin in March has yielded more than a good-looking plaque. Our products caught the attention of several interested parties including three of Europe’s largest pharmaceutical companies. We are actively exploring distribution and co-branding licensing proposals with all three. In each case these proposals offer significant potential advantages to the company. The most immediate would be product sales to companies with well-established, funded marketing and sales channels, and licensing agreements with royalty income. This strategy maintains our first-to-market advantage while giving us access to a good income stream and marketing power and access to capital (without further dilution). Another advantage would be the spill-over affect associated with this co-branding alliance on our other brands and obtaining additional distribution in other regions. http://www.bielcorp.com/investors/letter-from-the-president/
2014 Oxford Pharmascience Group (OXP) is sponsoring BIEL http://www.oxfordpharmascience.com/content/investors/share_price.asp
Park Lane Hotel, Piccadilly, London
Thursday, 6th March 2014
http://www.otc-bulletin.com/awards/pdfs/Nominations-Supplement-2014.pdf
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM